Business Description
Qurient Co Ltd
ISIN : KR7115180002
Compare
Compare
Traded in other countries / regions
115180.Korea IPO Date
2016-02-29Description
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 164.12 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 24.57 | |||||
Beneish M-Score | -1.63 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | -4.5 | |||||
3-Year FCF Growth Rate | 14.7 | |||||
3-Year Book Growth Rate | -25.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 65.98 | |||||
9-Day RSI | 62.95 | |||||
14-Day RSI | 58.59 | |||||
6-1 Month Momentum % | -18.67 | |||||
12-1 Month Momentum % | -36.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 18.42 | |||||
Quick Ratio | 18.34 | |||||
Cash Ratio | 17.78 | |||||
Days Inventory | 8.84 | |||||
Days Sales Outstanding | 36.71 | |||||
Days Payable | 11.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.9 | |||||
Shareholder Yield % | 0.39 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 19.11 | |||||
Operating Margin % | -241.84 | |||||
Net Margin % | -220.55 | |||||
FCF Margin % | -232.76 | |||||
ROE % | -66.03 | |||||
ROA % | -54.1 | |||||
ROIC % | -268.36 | |||||
ROC (Joel Greenblatt) % | -4116.31 | |||||
ROCE % | -61.29 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.66 | |||||
PB Ratio | 2.5 | |||||
Price-to-Tangible-Book | 2.67 | |||||
EV-to-EBIT | -3.98 | |||||
EV-to-EBITDA | -4.14 | |||||
EV-to-Revenue | 9.19 | |||||
EV-to-FCF | -4.37 | |||||
Price-to-Net-Current-Asset-Value | 3.11 | |||||
Price-to-Net-Cash | 3.18 | |||||
Earnings Yield (Greenblatt) % | -25.13 | |||||
FCF Yield % | -17.47 |